Response_Letter_HTH-2020-01556.pdf
Response_Package_HTH-2020-01556.pdf
FOI Request - HTH-2020-01556 Copies of: All Utilization Reviews and Drug reviews regarding the therapeutic evaluation of single drugs and drug classes referenced in Section 1 of Part 2 of Schedule A (entitled 'Services') to the Shared Cost Agreement ('Agreement') entered into by the Ministry of Health with the University of British Columbia, that have been completed since the commencement of the term of the Agreement, on October 1, 2017. We request that the response make clear which documents constitute the clinical evidence reviews referenced in Section 1(b)(i), which constitute the pharmacoeconomic reviews referenced in Section 1(b)(ii) and which constitute the therapeutic reviews referenced in Section 1(b)(iii); All pharmacoepidemiological studies and/or program evaluations completed since October 1, 2017, as referenced in Section 2 of Part 2 of the same Schedule A; All program materials and program evaluation documents pertaining to the Quality Prescribing Program completed since October 1, 2017, as referenced in Section 4(a) of Part 2 of the same Schedule A; All documents that identify suboptimal patterns of drug use and interventions to improve use completed since October 1, 2017, as referenced in Section 4(b) of Part 2 of the same Schedule A; All education programs to health care professionals and/or health care policy makers completed since October 1, 2017, as referenced in Section 5 of Part 2 of the same Schedule A; All systematic reviews completed for Cochrane Hypertension since October 1, 2017, as referenced in Section 6 of Part 2 of the same Schedule A. (Date Range for Record Search: From 10/1/2017 To 2/26/2020) FOI Request FOI Request 2024-10-04 Health 10 2024 Response_Letter_HTH-2020-01556.pdf Response_Package_HTH-2020-01556.pdf Law Firm $0.00